highlights asco gu...
TRANSCRIPT
![Page 1: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/1.jpg)
Highlights ASCO GU 2016
Neoplasie del testicolo
Ugo De Giorgi IRST-IRCCS Meldola
Milano, 22.01.2016
![Page 2: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/2.jpg)
Keynote Lectures Tom Powles, Rare and Testicular Cancers: Year in Review Torgrim Tandstad, Long-term Toxicity: What to Expect and How to Prevent It? Darren R. Feldman, Dose Intensification for First-line Therapy of Metastatic Disease: Which Patients and What Type of Intensification? Katherine L. Nathanson, What Does the Clinician Need to Know about the Molecular Genetics of Testicular Cancer?
Oral presentations ABSTRACT 472: Conditional survival of patients with metastatic testicular germ-cell tumors treated with first-line curative therapy. Author: Jenny J. Ko ABSTRACT 473: Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. Author: Aditya Bagrodia
![Page 3: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/3.jpg)
Keynote Lectures Tom Powles, Rare and Testicular Cancers: Year in Review Torgrim Tandstad, Long-term Toxicity: What to Expect and How to Prevent It? Darren R. Feldman, Dose Intensification for First-line Therapy of Metastatic Disease: Which Patients and What Type of Intensification? Katherine L. Nathanson, What Does the Clinician Need to Know about the Molecular Genetics of Testicular Cancer?
Oral presentations ABSTRACT 472: Conditional survival of patients with metastatic testicular germ-cell tumors treated with first-line curative therapy. Author: Jenny J. Ko ABSTRACT 473: Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. Author: Aditya Bagrodia
![Page 4: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/4.jpg)
Highlights ASCO GU 2016 Torgrim Tandstad, Long-term Toxicity: What to Expect and How to Prevent It? Darren R. Feldman, Dose Intensification for First-line Therapy of Metastatic Disease: Which Patients and What Type of Intensification?
ABSTRACT 473: Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. Author: Aditya Bagrodia
![Page 5: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/5.jpg)
Keynote Lecture Testicular Cancer<br />Long-term Toxicity: What to Expect and How to Prevent It?
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
Tossicità a lungo termine
![Page 6: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/6.jpg)
Why is long-term toxicity important in testicular cancer survivors (TCS)?
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 7: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/7.jpg)
The Future – Scope
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 8: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/8.jpg)
Slide 7
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 9: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/9.jpg)
Cardiovascular disease (CVD)
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 10: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/10.jpg)
Pulmonary disease
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 11: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/11.jpg)
Other toxicities
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 12: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/12.jpg)
Prevention of late effects – Clinical implications
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 13: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/13.jpg)
Risk-adapted treatment CS I
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 14: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/14.jpg)
CS I nonseminoma LVI+
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 15: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/15.jpg)
Experience or cooperation
Presented By Torgrim Tandstad at Genitourinary Cancers Symposium 2016
![Page 16: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/16.jpg)
Standards in First-Line Chemotherapy for High-Risk GCT: Does this Include Dose Intensification?
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
Intensità di dose in prima linea poor risk
![Page 17: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/17.jpg)
Do STM Decline Rates Predict PFS & OS?
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 18: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/18.jpg)
Could Treatment Change Benefit the Slow STM Decline Group?
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 19: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/19.jpg)
GETUG 13: Phase III Schema
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 20: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/20.jpg)
GETUG 13: PFS and OS in Randomized Pts
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 21: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/21.jpg)
GETUG 13: Conclusions & Questions
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 22: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/22.jpg)
Other Standards of Care and Common Questions / Pitfalls in Advanced GCT
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 23: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/23.jpg)
Pitfalls in Advanced GCT (Don’ts)
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 24: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/24.jpg)
Pitfalls in Advanced GCT (Don’ts)
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 25: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/25.jpg)
Risk of Substituting Carboplatin
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 26: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/26.jpg)
Risk of Decreasing Etoposide Dose
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 27: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/27.jpg)
How to Handle Neutropenia in GCT?
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 28: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/28.jpg)
Conclusions (Int/Poor Risk GCT)
Presented By Darren Feldman at Genitourinary Cancers Symposium 2016
![Page 29: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/29.jpg)
Actionable targets in advanced germ cell tumors
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
Nuovi target nei platino-resistenti?
![Page 30: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/30.jpg)
MSK IMPACT
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 31: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/31.jpg)
Methods
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 32: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/32.jpg)
Extreme non-responders: TP53/MDM2 alterations are found only in TGCT patients with platinum resistance
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 33: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/33.jpg)
Slide 12
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 34: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/34.jpg)
Potential Clinical Applications
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 35: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/35.jpg)
Actionable targets in resistant patients
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
IN CORSO: Studio fase 2 Olaparib nei GCT platino resistenti: IRST Meldola e Istituto Tumori Pascale Napoli
![Page 36: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/36.jpg)
Conclusions:
Presented By Aditya Bagrodia at Genitourinary Cancers Symposium 2016
![Page 37: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/37.jpg)
TAKE HOME MESSAGES
- Ridurre il “treatment burden”, nei casi iniziali - Nei casi avanzati a cattiva prognosi, mantenere alta la dose intensity - Possibili nuovi target, considerare studi clinici anche in Italia per forme platino-resistenti
![Page 38: Highlights ASCO GU 2016media.aiom.it/userfiles/files/doc/AIOM-Servizi/20160122MI_51_DeGiorgi.pdfHighlights ASCO GU 2016 Neoplasie del testicolo Ugo De Giorgi IRST-IRCCS Meldola Milano,](https://reader030.vdocuments.mx/reader030/viewer/2022040612/5f02577f7e708231d403cb9c/html5/thumbnails/38.jpg)
Italian Germ cell cancer Group (IGG)
Fondato nel 2005 per migliorare lo studio e la cura dei tumori germinali in Italia
Il gruppo conta oltre 100 iscritti, da circa 50 centri, principalmente oncologi, urologi e radioterapisti
Grazie per l’attenzione